These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 1650042)

  • 1. Combination therapy with ganciclovir and intravenous IgG for cytomegalovirus infections in pediatric liver transplant recipients.
    Megison SM; Andrews WS
    Transplantation; 1991 Jul; 52(1):151-4. PubMed ID: 1650042
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
    Mattes FM; Hainsworth EG; Geretti AM; Nebbia G; Prentice G; Potter M; Burroughs AK; Sweny P; Hassan-Walker AF; Okwuadi S; Sabin C; Amooty G; Brown VS; Grace SC; Emery VC; Griffiths PD
    J Infect Dis; 2004 Apr; 189(8):1355-61. PubMed ID: 15073671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ganciclovir therapy for cytomegalovirus disease in liver transplant recipients.
    Shaefer MS; Stratta RJ; Markin RS; Cushing KA; Woods GL; Reed EC; Wood RP; Langnas AN; Shaw BW
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1515-6. PubMed ID: 1846475
    [No Abstract]   [Full Text] [Related]  

  • 5. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocyte recovery in pediatric marrow transplant recipients treated with ganciclovir for cytomegalovirus infection.
    Roberts WD; Weinberg KI; Kohn DB; Sender L; Parkman R; Lenarsky C
    Am J Pediatr Hematol Oncol; 1993 Aug; 15(3):320-3. PubMed ID: 8392303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of ganciclovir followed by high-dose oral acyclovir vs ganciclovir alone in the prevention of cytomegalovirus disease in pediatric liver transplant recipients: preliminary analysis.
    Green M; Reyes J; Nour B; Beatty D; Kaufman M; Wilson J; Todo S; Tzakis A
    Transplant Proc; 1994 Feb; 26(1):173-4. PubMed ID: 8108926
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytomegalovirus prophylaxis with ganciclovir, acyclovir, and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction.
    Ham JM; Shelden SL; Godkin RR; Posner MP; Fisher RA
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):31-3. PubMed ID: 7482814
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
    Winston DJ; Busuttil RW
    Transplantation; 2004 Jan; 77(2):305-8. PubMed ID: 14742998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative CMV-antigenemia test in the diagnosis of CMV infection and in the monitoring of response to antiviral treatment in liver transplant recipients.
    Lautenschlager I; Höckerstedt K; Salmela K
    Transplant Proc; 1994 Jun; 26(3):1719-20. PubMed ID: 8030100
    [No Abstract]   [Full Text] [Related]  

  • 12. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreasing incidence of serious cytomegalovirus infection using gancyclovir prophylaxis in pediatric liver transplant patients.
    Boudreaux JP; Hayes DH; Mizrahi S; Maggiore P; Blazek J; Dick D
    Transplant Proc; 1993 Apr; 25(2):1872. PubMed ID: 8385825
    [No Abstract]   [Full Text] [Related]  

  • 14. Ganciclovir therapy for viral disease in liver transplant recipients.
    Stratta R; Shaefer M; Markin R; Bradshaw K; Donovan J; Wood R; Langnas A; Reed E; Woods G; Zetterman R
    Transplant Proc; 1991 Jun; 23(3):1968. PubMed ID: 1648277
    [No Abstract]   [Full Text] [Related]  

  • 15. Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study.
    Pescovitz MD; Brook B; Jindal RM; Leapman SB; Milgrom ML; Filo RS
    Clin Transplant; 1997 Dec; 11(6):613-7. PubMed ID: 9408695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganciclovir in the treatment of severe cytomegalovirus disease in liver transplant patients.
    Salmela K; Höckerstedt K; Lautenschlager I; Eklund B; Isoniemi H; Holmberg C; Ahonen J
    Transplant Proc; 1990 Feb; 22(1):238-40. PubMed ID: 2155492
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of early treatment of cytomegalovirus infection by ganciclovir in renal transplant recipients.
    Rondeau E; Farquet C; Ruedin P; Fries D; Sraer JD
    Transplant Proc; 1990 Aug; 22(4):1813-4. PubMed ID: 2167536
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.
    Mylonakis E; Kallas WM; Fishman JA
    Clin Infect Dis; 2002 May; 34(10):1337-41. PubMed ID: 11981729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of CMV-DNA in peripheral blood leukocytes of liver transplant patients after ganciclovir treatment.
    Loginov R; Höckerstedt K; Lautenschlager I
    Arch Virol; 2003 Jul; 148(7):1269-74. PubMed ID: 12827460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cytomegalovirus in liver transplantation: incidence and groups at risk].
    Schiffer V; Mentha G; Giostra E; Belli D; Le Coultre C; Rohner A
    Schweiz Med Wochenschr; 1994 Apr; 124(15):631-6. PubMed ID: 8191266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.